

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan
for the purchase or sale of equity
securities of the issuer that is
intended to satisfy the affirmative
defense conditions of Rule 10b5-
1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>GARRETT SCOTT T</u> (Last) (First) (Middle) <u>C/O HCW BIOLOGICS, INC.</u> <u>2929 N. COMMERCE PARKWAY</u> (Street) <u>MIRAMAR, FL 33025</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>HCW Biologics Inc. [HCWB]</u> Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) <u>07/29/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ☒ Director 10% Owner Officer (give title below) Other (specify below) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person
--	--	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/29/2026		P ⁽¹⁾		7,736	A	\$2.585	41,644	I	By LLC ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

1. The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 7,736 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.

2. Mr. Garrett is deemed to beneficially own the shares held by Garrett Capital Partners, LLC.

/s/ Nicole Valdivieso, as
Attorney-in-Fact for Scott T. 07/31/2026
Garrett

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.